AI Article Synopsis
- The study aimed to compare the outcomes of patients with bacteremic pneumonia caused by different pathogens over a period from 2016 to 2019.
- A total of 162 patients were analyzed, revealing a 30-day mortality rate of 43.75% for the KP-BP group compared to 21.95% for the -BP group, indicating significant differences in prognosis.
- The research found that KP-BP patients faced higher mortality risks under certain conditions like being in intensive care or having resistant infections, whereas the Pitt bacteremia score was a key predictor of mortality for patients in the -BP group.
Article Abstract
Objectives: To compare the prognosis of bacteremic pneumonia caused by () and () pathogens.
Methods: A retrospective analysis was carried out on the clinical data of 162 patients who were diagnosed with bacterial pneumonia caused by either or between 2016-2019. The primary outcome of the analysis was the patients' 30-day mortality rate.
Results: There were 82 patients in the bacteremic pneumonia (-BP) group and 80 patients in the bacteremic pneumonia (KP-BP) group. The 30-day mortality rate was 43.75% (n=35/80) in the KP-BP group and 21.95% (n=18/82) in the -BP group (<0.001). Following the adjustment for confounding variables in 4 distinct models, the hazard ratios for the primary outcome in KP-BP were determined to be 0.70 (95% confidence interval [CI]: [0.44-1.02]) in Model 1, 0.72 (95% CI: [0.46-1.14]) in Model 2, 0.99 (95% CI: [0.57-1.73]) in Model 3, and 1.22 (95% CI: [0.69-2.18]) in Model 4.
Conclusion: Patients diagnosed with KP-BP exhibited a similar prognosis as those diagnosed with -BP. For patients with KP-BP, the risk of mortality was significantly higher for those who were in the intensive care unit, were infected with carbapenem-resistant strains, or had a high sequential organ failure assessment score. In patients with -BP, the Pitt bacteremia score was strongly associated with the 30-day mortality rate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11115389 | PMC |
| http://dx.doi.org/10.15537/smj.2024.45.3.20230428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health state utilities associated with invasive pneumococcal disease, pneumonia, and recurrent acute otitis media in young children.
Qual Life Res
January 2025
MRL, Merck & Co., Inc., Rahway, NJ, USA.
Purpose: Cost-utility analyses examining the value of new vaccines for pneumococcal disease will require health state utilities as inputs. Existing utilities for pneumococcal infections in young children are limited. The purpose of this study was to estimate health state utilities associated with pneumococcal infections in young children.
View Article and Find Full Text PDFSystematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.
Vaccine
December 2024
Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA. Electronic address:
Article Synopsis
- The review examined cost-effectiveness analyses of new adult pneumococcal vaccines (PCV15 and PCV20) across different countries.
- Most studies found that PCV20 offered cost savings or was more cost-effective than older vaccination strategies in high-income countries.
- Assumptions about vaccine effectiveness, duration of protection, and herd immunity effects varied, with most studies considered low-risk for bias.
PNEUMOCOCCAL SEROTYPE DISTRIBUTION AND COVERAGE OF EXISTING AND PIPELINE PNEUMOCOCCAL VACCINES.
medRxiv
December 2024
School of Public Health, University of California, Berkeley, Berkeley, California, United States.
Background: (pneumococcus) causes invasive pneumococcal disease (IPD) and non-invasive acute respiratory infections (ARIs). Three pneumococcal conjugate vaccines (PCVs) are recommended in the United States with additional products in clinical trials. We aimed to estimate 1) proportions of IPD cases and pneumococcal ARIs caused by serotypes targeted by existing and pipeline PCVs and 2) annual U.
View Article and Find Full Text PDFHealth and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach.
J Med Econ
December 2025
Merck & Co., Inc, Rahway, NJ, USA.
Introduction: This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach.
Methods: A Markov model was employed to simulate the movement of the Japanese population among four health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae, and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level.
Invasive pneumococcal disease in adults after the introduction of pneumococcal vaccination: a retrospective study in the metropolitan area of Zagreb, Croatia (2010-2022).
Front Public Health
December 2024
University Hospital Dubrava, Zagreb, Croatia.
Introduction: Invasive pneumococcal disease (IPD) is a severe form of illness caused by with high morbidity and mortality rate in the general population, particularly in children <5 years of age, adults ≥65 years of age and the immunocompromised. As known, pneumococcal vaccination lowers the risk of IPD so the aim of this study was to investigate whether the introduction of pneumococcal vaccination has influenced the incidence and mortality of IPD in adults in Croatia.
Materials And Methods: A retrospective study was conducted among adult patients (aged ≥18 years) hospitalized due to IPD in the metropolitan area of Zagreb from 1 January 2010 to 31 December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!